VIDEO: Natural killer cell therapies for B-cell lymphoma perform "surprisingly well"
Click Here to Manage Email Alerts
In this video, Joshua Sasine, MD, PhD, discusses a set of abstracts presented at ASH that evaluated natural killer cell therapies such as FT596 and FT516 in patients with relapsed/refractory B-cell lymphoma.
“I was pleasantly surprised with how well they performed in a small number of patients," Sasine, assistant professor of medicine hematology and cellular therapy at Samuel Oschin Cancer Center Regenerative Medicine Institute, said.
There was virtually no inflammatory toxicity, with results comparable with chimeric antigen receptor T-cell therapy, he said.
"I think the main question people will be asking is what will be the durability of these? We truly don't know, but my hunch is that it will actually be fairly durable," Sasine said.
Collapse
Bachanova V, et al. Abstract 823. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Patel K, et al. Abstract 3873. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.
Click Here to Manage Email Alerts